DEADLINE ALERT for EXAI, AKRO, and MBUU: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
June 25, 2024 09:48 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, June 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
June 24, 2024 13:10 ET
|
The Rosen Law Firm PA
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between...
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 24, 2024 13:04 ET
|
Lowey Dannenberg, P.C.
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”)...
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 21, 2024 11:06 ET
|
Lowey Dannenberg, P.C.
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”)...
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 19, 2024 14:45 ET
|
Lowey Dannenberg, P.C.
NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”)...
Akero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
June 17, 2024 14:26 ET
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Akero Therapeutics, Inc....
DEADLINE ALERT for CMP, EXAI, AKRO, and MBUU: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
June 17, 2024 12:14 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 17, 2024 10:23 ET
|
Lowey Dannenberg, P.C.
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”)...
AKRO ANNOUNCEMENT: If You Have Suffered Losses in Akero Therapeutics, Inc. (NASDAQ: AKRO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
June 16, 2024 11:18 ET
|
The Rosen Law Firm PA
NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13,...
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 13, 2024 15:57 ET
|
Lowey Dannenberg, P.C.
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”)...